{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/148853480"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Clinicians and regulators worry over side effects, particularly the risk of developing a rare neurological condition progressive multifocal leukoencephalopathy (PML), the brain infection that bedevils the -4 integrin antagonist Tysabri (natalizumab), co-marketed by Biogen Idec, of Cambridge, Massachusetts, and Dublin-based Elan." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "thisisms.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/310955789"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/148853480"] } } }
